Skip to main content

Table 2 Baseline characteristics of included patients

From: A new method for treating fecal incontinence by implanting stem cells derived from human adipose tissue: preliminary findings of a randomized double-blind clinical trial

Variable Total Control group hADSC-treated group p
Age (median, IQR) 40.2 (25) 38.5 (22) 36.0 (22) 0.45*
Gender (n, %)
 Male 4 (22.22) 2 (22.22) 2 (22.22) 0.71#
 Female 14 (77.78) 7 (77.78) 7 (77.78)  
History of GI diseases (n, %)
 No 13 (72.22) 6 (77.78) 6 (66.67) >0.99#
 Yes 5 (27.78) 2 (22.22) 3 (33.33)  
Number of deliveries (n, %)
 0 7 (41.18) 2 (25.0) 5 (55.56) 0.22#
 1 7 (41.18) 5 (62.50) 2 (22.22)  
 2 2 (11.78) 0 (0.0) 2 (22.22)  
 3 1 (5.88) 1 (12.50) 0 (0.0)  
Rectal urgency (n, %)
 No 18 (100.0) 9 (100.0) 9 (100.0) >0.99#
 Yes 0 (0.0) 0 (0.0) 0 (0.0)  
History of anal surgery (n, %)
 No 11 (61.11) 5 (55.56) 6 (66.67) >0.99#
 Yes 7 (38.89) 4 (44.44) 3 (33.33)  
History of urinary urgency (n, %)
 No 18 (100.0) 9 (100.0) 9 (100.0) >0.99#
 Yes 0 (0.0) 0 (0.0) 0 (0.0)  
  1. IQR interquartile range, GI gastrointestinal, control group sphincteroplasty alone, hADSC-treated group human adipose-derived stem cells + sphincteroplasty
  2. *Based on Mann–Whitney U test
  3. #Based on Fisher’s exact test